Balance Sheet
Cash Flow Statement
Daily Values
DMA 100DMA 200DMA 50Dividend YieldEV to CFOEV to EBITEV to EBITDAEV to FCFEV to RevenueEnterprise ValueMarket Cap to FCFMarket CapitalizationPricePrice to EarningsPrice to Sales
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

KalVista Pharmaceuticals (KALV) Enterprise Value (2016 - 2026)

KalVista Pharmaceuticals' Enterprise Value history spans 11 years, with the latest figure at -$220.6 million for Q2 2025.

  • On a quarterly basis, Enterprise Value fell 4.86% to -$220.6 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$220.6 million, a 4.86% decrease, with the full-year FY2025 number at -$220.6 million, down 4.86% from a year prior.
  • Enterprise Value hit -$220.6 million in Q2 2025 for KalVista Pharmaceuticals, up from -$268.3 million in the prior quarter.
  • Over the last five years, Enterprise Value for KALV hit a ceiling of -$50.3 million in Q1 2021 and a floor of -$268.3 million in Q4 2024.
  • Historically, Enterprise Value has averaged -$160.0 million across 4 years, with a median of -$149.4 million in 2023.
  • The widest YoY moves for Enterprise Value: up 37.56% in 2021, down 267.62% in 2021.
  • Tracing KALV's Enterprise Value over 4 years: stood at -$248.9 million in 2021, then soared by 58.55% to -$103.2 million in 2023, then plummeted by 160.09% to -$268.3 million in 2024, then increased by 17.79% to -$220.6 million in 2025.
  • Business Quant data shows Enterprise Value for KALV at -$220.6 million in Q2 2025, -$268.3 million in Q4 2024, and -$135.8 million in Q4 2024.